| Abstract | Metastatic breast carcinoma in men is usually responsive to hormonal therapy. Most ablative and additive hormonal therapies reported have had objective response rates in excess of 50%. Anastrozole has excellent antitumor activity in postmenopausal women, but no data exist on its efficacy in men. Medical records for all men with a diagnosis of breast cancer who were treated at M. D. Anderson from 1990 to 1999 were reviewed. Five male patients with metastatic breast cancer who were treated at M. D. Anderson with anastrozole were identified. We now report on these five cases. |
| Authors | Sharon H Giordano, Vicente Valero, Aman U Buzdar, Gabriel N Hortobagyi
(Affiliation: University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.)
|
| Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 25
Issue 3
Pg. 235-7
(Jun 2002)
ISSN: 0277-3732 United States |
| PMID | 12040279
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Enzyme Inhibitors
- Nitriles
- Triazoles
- anastrozole
|
| Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Aromatase Inhibitors
- Bone Neoplasms
(drug therapy, secondary)
- Breast Neoplasms, Male
(drug therapy, pathology, therapy)
- Combined Modality Therapy
- Enzyme Inhibitors
(therapeutic use)
- Humans
- Lung Neoplasms
(drug therapy, secondary)
- Lymphatic Metastasis
- Male
- Middle Aged
- Nitriles
(therapeutic use)
- Treatment Failure
- Triazoles
(therapeutic use)
|
